Impact Biomedical (IBO) Depreciation & Amortization (CF) (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $285000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 0.71% year-over-year to $285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 2.23% YoY) and the FY2025 annual result came in at $1.1 million, up 2.32% from the prior year.
• Depreciation & Amortization (CF) steadied at $285000.0 in Q1 2026, from $286000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $288000.0 in Q2 2025 to a low of $278000.0 in Q4 2022.
• A 5-year average of $281733.3 and a median of $280000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) retreated 0.36% — and 2025, when it advanced 3.23%.
• Tracing IBO's Depreciation & Amortization (CF) over 5 years: stood at $278000.0 in 2022, then gained by 0.72% to $280000.0 in 2023, then decreased by 0.36% to $279000.0 in 2024, then climbed by 2.51% to $286000.0 in 2025, then retreated by 0.35% to $285000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $285000.0 (Q1 2026), $286000.0 (Q4 2025), and $288000.0 (Q3 2025), per Business Quant data.